Resources

Cabozantinib Ipsen therapeutic indications

Cabozantinib Ipsen^® is indicated as monotherapy for advanced renal cell carcinoma:

as first-line treatment of adult patients with intermediate or poor risk,
in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

Cabozantinib Ipsen, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

Real World Experience

HCP experience of using cabozantinib + nivolumab to treat patients with aRCC

Video 03:18

Hear from Prof. Laurence Albiges and Prof. James Larkin sharing their experience of using Cabo+Nivo to treat patients with aRCC.

CBZ-UK-000344 | November 2024

Supporting Patients with aRCC during treatment with cabozantinib + nivolumab

Video 04:28

Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.

CBZ-UK-000345 | November 2024

Importance of cabozantinib + nivolumab for the treatment of aRCC

Video 05:40

Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.

CBZ-UK-000341 | November 2024

Adverse Event Management

IO/TKI Toxicity – How to work out which toxicities are coming from which drug

Video 17:10

Toxicity Management with combination treatment – How to work out which toxicities are coming from which drug.

CBZ-UK-000346 | November 2024

Identification and management of adverse reactions with cabozantinib in patients with advanced renal cell carcinoma

PDF / PowerPoint Deck 17 pages

A guide for healthcare professionals

CBZ-UK-000342 | November 2024

Product Resources

Checkmate 9ER Trial: Data Summary

Early efficacy with sustained long-term overall survival vs sunitinib: At a median follow-up of 67.6 months (60.2 months minimum), CheckMate 9ER data for Cabozantinib + nivolumab demonstrate an 11-month longer mOS vs sunitinib.

CBZ-UK-000470 | March 2025